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Abstract
Background: High flow nasal cannula therapy is becoming a more common therapy in the adult
population. Multiple studies have been conducted on the potential benefits of this therapy such as
increased patient tolerance of the therapy, improved secretion clearance and the ability for providers to
deliver a greater range of FiO2 settings at a wider range of flow rates. With the increasing utility of this
therapy, the research for best practices, setting (FiO2 and LPM) and duration of therapy to guide
clinicians is lacking.
Aim: 1) Does high flow nasal cannula therapy reduce the need for intubation or re-intubation in patients
with hypoxic respiratory failure, as compared to continuous positive airway pressure or bi-level positive
airway pressure therapy? 2) How do variations in setting of high flow nasal cannula therapy affect the
need for intubation or re-intubation, mortality and hospital length of stay?
Methods: Subjects for this study were adults, ages 18-99 years old with a diagnosis of respiratory failure.
Group 1 (n=213) was created to determine whether initial high flow treatment for respiratory failure may
decrease intubation rates, as compared to continuous positive airway pressure or bi-level positive airway
pressure therapy. Group 2 (n=88) examined whether high flow nasal cannula therapy was associated with
lower re-intubation rates when high flow was administered to post ventilator respiratory failure patients.
An in-group analysis of high flow nasal cannula therapy was done in both groups to examine how
variation in setting affected patient outcomes. Statistical analysis was performed with SPSS version 24.
Results: In Group 1, the analysis of high flow nasal cannula therapy vs. continuous positive airway
pressure or bi-level positive airway pressure therapy found no significant difference in intubation rates,
p=0.119. No significant difference was found between type of NIV therapy used for post extubation
patients and the rate of re-intubation for Group 2, p=0.789. In-group analysis of high flow cannula setting
(FiO2 and LPM) found that there was no significant difference associated with high flow administration
and reduced mortality in Group 1 (FiO2 p=0.0988, LPM p=0.502 or Group 2 (FiO2 p=0.194, LPM
p=0.449). There was no significant difference in the need for intubation or re-intubation in both Group 1
(FiO2 p=0.992, LPM p=0.716) and Group 2 (FiO2 p=0.746, LPM p=0.592).
Conclusion: This study suggests that high flow nasal cannula therapy performed similarly as continuous
positive airway pressure or bi-level positive airway pressure therapy in preventing intubation and reintubation rates. The group analysis of high flow nasal cannula therapy settings suggests that variation in
the setting did not impact intubation or re-intubation rates.
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Background
High flow nasal cannula (HFNC) therapy is a noninvasive ventilation (NIV) modality that has
recently gained increased attention in the adult critical care world. This form of noninvasive ventilation
allows for the delivery of warm, humidified oxygen therapy with a FiO2, the percentage of oxygen
inspired, of 0.21-1 and flow rates up to 60 liters per minute (LPM) (Nishimura, 2016). HFNC therapy
allows for a more predictable delivery of FiO2 than other noninvasive ventilation strategies (Nishimura,
2016). In addition, HFNC therapy has the ability to improve oxygenation (Stephan et al., 2015; Cirio et
al., 2016) and decreases the work of breathing (Stephan et al., 2015; Roca, Riera, Torres, & Masclans,
2010). In a study by Frat et al. (2015), patients with a pO2/FiO2 ratio of < 200 HFNC showed a reduced
need for intubation when compared to standard oxygen therapy (i.e., low flow oxygen therapy) and other
noninvasive ventilation modalities, p=0.01. This open label, multicenter, randomized control studyf
examined the effects that HFNC therapy had on clinical outcomes and intubation rates in acute respiratory
failure patients admitted to the intensive care unit (ICU). The population consisted of adult patients, 1899, admitted to the ICU with respiratory failure secondary to community acquired pneumonia, hospital
acquired pneumonia, extra pulmonary sepsis, aspiration/drowning, pneumonia related to
immunosuppression and other causes (Frat et al., 2015). This study also found that HFNC therapy leads
to a significant reduction in ICU mortality, standard oxygen therapy vs. HFNC therapy p=0.046 and
HFNC therapy vs. noninvasive ventilation p=0.006. Strengths of this study were that it followed a welldelineated research protocol, and pre determined definition of the need for intubation, and multicenter
design. A limitation of this study was that blinding of therapy delivered was in the selection of setting for
HFNC therapy, as there was no documented justification for the setting used in the study. In the study by
Frat et al. (2015), the potential for bias was addressed by having the data masked until collection was
completed.
HFNC therapy was also found to have clinical benefits when applied post extubation. When
compared to BiPAP, HFNC was found to be non-inferior in reducing the rate of re-intubation (Hernadez
et al., 2016; Stephan et al., 2015). Both of these studies were well-designed, multicenter, prospective,
randomized control trials. Hernadez et al. (2016) examined how HFNC therapy could affect re-intubation
rates in patients that experienced post extubation acute respiratory failure. This study evaluated how
HFNC performed vs. CPAP and BiPAP in reducing the re-intubation rates in patients deemed high risk
for the need to be re-intubated. In the study by Stephan et al. (2015), researchers examined if HFNC was
inferior to BiPAP in preventing or reducing acute respiratory failure in postoperative cardiothoracic
patients. Both studies followed a well-delineated study protocol and predetermined definition of outcomes
to conduct their collection and analysis. A limitation for both of these studies is that there is no
documented justification for the settings that were used in the study. In Hernandez et al. (2016), the
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selection criteria for patient inclusion was for patients that are at higher risk for intubation, which could
have skewed results. In addition, no current literature provides any evidences for a tool to identify these
patients. An additional limitation of Stephan et al. (2015) is that the therapies were not blinded. This
could potentially have resulted in bias in the data collection process.
The current state of literature has been focused on the potential benefits of HFNC study. In the
field of HFNC therapy, research or Medical Society Consensus Statements examining the best practices
for FiO2 and LPM setting to guide clinicians are currently lacking. This is due to the lack of current
literature examining the affects from variation in therapy. It is to our knowledge that no previous studies
have been conducted to evaluate the equipoise of practice for HFNC therapy settings.
Aim
This study examined a single quaternary academic medical center’s current practices of high flow
nasal oxygen administration to identify trends in practice for variability. In addition, this study looked at
how current practices in HFNC therapy relate to the subsequent need for intubation or re-intubation,
patient mortality, length of stay and time on NIV in acute respiratory failure patients. This study will also
examine how HFNC therapy, compared to CPAP/BiPAP, affects the need for intubation or re-intubation,
mortality, length of stay and time mechanical ventilation. This study will examine a single center’s
administration of oxygen therapies prior to intubation and post-intubation in patients with acute
respiratory failure. In addition, this study will examine the effects that variations in HFNC therapy
settings have on patient outcomes. This study will help establish whether equipoise exists in the current
single center’s practice. Information from this study may help define future study groups in order to
define which HFNC parameters may be best, or define which disease states might benefit most from
administration of HFNC therapy.
Methods
Design
This study was a non-experimental, descriptive, retrospective medical record review.
Subjects
Subjects included in this study consisted of adults 18-99 years old that developed or presented
with acute respiratory failure and were admitted to UK Chandler Hospital and received NIV therapy
during their stay. Exclusion criteria included patients with tracheostomy or do-not-intubate status. For
inclusion in this study, each instance of NIV therapy recorded was designed, in order to be considered
evaluable, to simultaneously coincide with a hypoxic event documented within the electronic medical
record. Hypoxia for this study was defined as a SpO2 < 92%, RR>20 per minute, heart rate >100 beats
per minute and a PaO2 of less than 80. This criterion was adapted from definitions of hypoxia from
previous studies, Frat el al. (2015), Hernadez et al. (2016), Roca, et al. (2010) and Stephan et al. (2015).
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Each event of NIV needed documentation of at least one of these variables up to four hours prior to the
initiation of therapy. If a patient had an additional encounter of NIV therapy documented within 12 hours
of the previous NIV therapy documentation, the additional encounter was considered to be treating the
same hypoxic event. This study is designed so that for NIV therapy to be considered successful in
preventing intubation, the subjects could not have been intubated and placed on mechanical ventilation
within 12 hours of the last NIV documentation. To determine if NIV therapy is successful in reducing the
need for re-intubation, subjects re-intubated within 48 hours of extubation were considered as failing NIV
therapy.
A sample size of 400 patients was selected to ensure that the study was adequately powered to
detect a moderate correlation and from parameters in previous randomized controlled trials (Hernadez et
al., 2016; Stephan et al., 2015). An electronic medical record review of the Sunrise Clinical Manager
(SCM) database was conducted to identify BiPAP, CPAP and HFNC use in the emergency department,
ICUs and floors of UK Medical Center. The time frame for this medical record review was July 1, 2014July 1, 2016. The initial search of SCM data based produced 46,218 unique patient encounters, Figure 1.
From this patient pool, those with a primary or secondary diagnosis of acute respiratory failure and solely
receiving HFNC or CPAP or BiPAP were to be included for this study. This gave the final pool of 1,885
patients, 329 HFNC, 1,227 CPAP or BiPAP and 329 that received both therapies. From these patients, a
computerized random number generator was used to select 200 that only received HFNC therapy and 200
patients that only received CPAP or BiPAP. These patients made up the final sample of patients for this
study. The sample for this study was further divided in to two groups. Group 1 comprised of patients
that received either HFNC therapy or CPAP or BiPAP and the initial form of NIV therapy as initial
treatment prior to the need for intubation. Group 2 comprised of patients that received HFNC therapy or
CPAP or BiPAP after liberation from mechanical ventilation. Of the 400 patients, 308 meet the inclusion
criteria for Group 1. Of the 308 patients, 95 had to be excluded from the study due to improper
documentation of NIV, NIV setting and discharge disposition. This left 213 patients to be included in the
sample for Group 1. In Group 2, 92 patients were originally selected, but four had to be excluded due to
incomplete charting and missing data, leaving the final sample at 88.
Data Collection
General patient characteristics (age, gender) and primary diagnosis were collected. Data
collection for HFNC, BiPAP and CPAP began at the documented time the therapy was started. Hourly
documented settings of HFNC, BiPAP and CPAP were collected. If no documentation for an hour was
available, the settings from the previous hour were used. For BiPAP, CPAP and HFNC, the amount of
time that a subject was on a therapy was collected. Onset of therapy was defined as the first
documentation of settings for HFNC, BiPAP and CPAP. The cessation of therapy was defined as the
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documented time that HFNC, BiPAP and CPAP were discontinued or the time that another oxygen
supportive therapy was documented. The time of intubation was the time that post intubation chest x-rays
were obtained to confirm endotracheal tube placement or the documentation of mechanical ventilation
settings.
Arterial blood gases (ABGs) documented within four hours to the initiation/change in oxygen
therapy of therapy will be collected. The nearest documented vital signs (heart rate, blood pressure,
respiratory rate and SpO2) and oxygen settings (L/min) to 0700, 1100,1300,1700, 2100, 2400 (0000) and
0300 hours were collected.
Time on mechanical ventilation was collected. The first documented ventilator settings of the
day were recorded until the time of extubation. The time of extuabtion was determined to be the
documentation of extubation or initiation of a different oxygen supportive therapy. Ventilator days were
defined as any portion within a calendar day on mechanical ventilation. Hospital length of stay was
calculated as the documented time of admission to the documented time of disposition (discharge or
death). Diagnosis related groups were collected on for each subject on the time of discharge. Disposition
location was collected. Data collection was done through the Center for Health Service Research. See
Table 1 for data points recorded.
Plan for Analysis
Descriptive statistics were used to summarize the study sample using means and standard
deviations, medians and ranges or frequencies and percentages. The Chi-square test of association was
used to compare mortality by patient category. The Mann-Whitney U test was used to compare groups on
non-normal clinical variables (hospital length of stay, time on mechanical ventilation and time on
noninvasive ventilation). An in-group analysis of HFNC therapy was done with the Mann-Whitney U
and Kruskal-Wallis test, where appropriate, to assess how changes in FiO2 and LPM could affect the need
for intubation, hospital length of stay, mortality, time on noninvasive therapy and time on mechanical
ventilation. All data analysis was conducted using SPSS, version 24, with an alpha level of .05.
Results
Group 1: HFNC vs. CPAP or BiPAP and Intubation
Group 1 was created to examine the effects of HFNC therapy vs. CPAP or BiPAP on preventing
the need for intubation when delivered as initial therapy in patients with acute respiratory failure. In this
group, there was even distribution between patient groups, those receiving HFNC (n=88) therapy and
those receiving CPAP or BiPAP (n=125). Between HFNC therapy and CPAP or BiPAP, there was no
significant difference between age (p=0.188) and sex (p= 0.216). In each group, there was a similar
distribution of men and women. This is shown in Table 2. As determined by DRG weighting, there was
a significant difference in the patient acuity between HFNC therapy and CPAP or BiPAP, p= 0.046.
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Table 2 shows that patients that received HFNC therapy had a higher median DRG weight than those in
the CPAP or BiPAP group, 3.16 vs. 1.88. The difference in DRG-determined acuity may also explain the
significant difference in the hospital length of stay between HFNC therapy and CPAP or BiPAP, p=
0.048. Patients that received HFNC therapy had a median hospital length of stay of 14.82 days, and
patients that received CPAP or BiPAP had a 10.65 days median hospital length of stay, a difference of
4.17 days.
Comparing CPAP or BiPAP vs. HFNC therapy for the duration of NIV treatment, a MannWhitney U test indicated a significant difference between therapies and the amount of time subjects were
on therapy, HFNC 6.50 hours, CPAP or BiPAP 4.00 hours, p=<0.001. A Mann-Whitney U test indicated
a significant difference in hospital length of stay, p=0.048. A Chi-square test, with Yates Continuity
Correction, was conducted to assess the association of HFNC therapy and mortality. The percentage of
subjects that expired was similar between groups, 22.4% (28) in the CPAP or BiPAP group and 27.3%
(24) for subjects receiving HFNC therapy, p= 0.415, Table 2. HFNC therapy was compared to CPAP or
BiPAP to determine if one therapy was associated with a reduction in respiratory failure and a patient’s
need for intubation, Table 3. A Chi-square test, with Yates Continuity Correction, indicated no difference
in intubation rates between HFNC therapy or CPAP or BiPAP, p=0.119. There was no difference in the
number of days a subject was on mechanical ventilation post NIV therapy, p=0.801.
A secondary analysis of patients in Group 1 who received HFNC therapy was done. This
secondary analysis was done to determine if different initial settings for FiO2 and LPM had any
significant association with the need for intubation, and to determine if the settings impacted clinical
outcomes, Table 4 and Table 5. Between initial settings for LPM, no significant difference was found in
patient acuity, p=0.692 (Table 5). However, for the subjects in Group 1, there was significant difference
in initial FiO2 settings and the acuity of the patient, p=0.003 (Table 4). There was no significant
difference between the quartiles of initial LPM (p=0.716) and FiO2 (p=0.992) and the need for intubation,
Table 4 and Table 5. The comparison of initial FiO2 and LPM setting and mortality was also assessed to
decipher which setting was associated with reduced mortality. Findings for this comparison showed no
significant difference in mortality in initial FiO2 (p=0.099) and LPM settings (p=0.502). When looking
at variation in initial FiO2 setting, no significant difference was found between hospital length of stay,
p=0.062, and time patients were on the ventilator post intubation, p=0.082. There was no significant
difference between initial LPM setting and hospital length of stay, p=0.476. Variation in setting of initial
LPM delivered to the patient was found to have a significant impact on the amount of time a patient was
mechanically ventilated after receiving HFNC therapy, p=0.046. No significant difference, p= 0.476, was
found in patient length of stay among different flow rates. No significant difference was found between
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initial FiO2 settings and duration of NIV, p=0.103. However, there was a significant difference between
flow rate settings and the duration of NIV therapy, p=0.033.
Group 2 HFNC vs. CPAP or BiPAP and Re-intubation
Of the 88 patients in Group 2, 62 (70.45%) received HFNC therapy and 26 (29.55%) received
CPAP or BiPAP. Between HFNC therapy and CPAP or BiPAP, there was a significant difference in the
age of the patients, p= 0.048 (Table 6). As shown in Table 6, there was no statistical difference in the
gender distribution between HFNC and CPAP or BiPAP, p= 0.376. For patient acuity, there was no
statistical difference between HFNC therapy (5.17) and CPAP or BiPAP (5.37), p= 0.905.
When assessing HFNC therapy’s effect on hospital length of stay, there was no significant
difference as compared to CPAP or BiPAP (16.08 vs. 18.16 days), p=0.387. Between HFNC therapy and
CPAP or BiPAP, there was no significant difference in mortality, HFNC vs. CPAP or BiPAP, p=0.975.
In comparing the need for re-intubation, no significant difference, p=0.969, was found between NIV
therapies. As with the finding in Group 1, subjects received HFNC therapy a significantly longer amount
of time than subjects on CPAP or BiPAP, p=<0.001. This study found that there was a significant
difference in the delay of initiation of NIV therapy post extubation and the need for a patient to be reintubated, p=0.075.
A secondary in-group analysis of HFNC therapy was performed to establish if there was any
difference between FiO2 settings and LPM and re-intubation. There was no significant difference across
quartiles for both FiO2 (p=0.746) and LPM (p=0.592) and re-intubation. For mortality and differences in
FiO2 therapy (p=0.194) and LPM (p=0.449) setting, no significant association was established between
HFNC and mortality. Variation in initial HFNC setting of FiO2 (p=0.145 and LPM (p=0.582) had no
significant association with hospital length of stay.
Discussion
Findings
The analysis comparing NIV therapies (HFNC vs. CPAP or BiPAP) showed that there was no
significant difference in the ability of either therapy to reduce the rate of intubation. This finding is
consistent with the Frat et al. (2015) conclusion that HFNC therapy has no significant effect on the
intubation of subjects with hypoxic respiratory failure. These findings suggest that HFNC therapy is noninferior to CPAP or BiPAP in reducing the need for intubation. Subjects in this study on NIV had a lower
rate of intubations than seen in Frat et al (2015). This could be due to the inclusion criteria for the
subjects. In this study, subjects who developed a secondary diagnosis of respiratory failure were
included. Subjects who developed respiratory failure in the hospital could have received interventions to
treat their respiratory failure sooner than the subjects in Frat el al. (2015) that presented with the primary
diagnosis of respiratory failure. The difference in the ability to detect a significant difference between
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groups could be due to this study being underpowered. It could also be attributed to the difference in
mortality in-groups. Another factor that could affect the difference in mortality rates between this study
and Frat et al. (2015) is that patients in this study could have had a higher acuity. It is impossible to
determine if there was a difference in acuity because different measures of acuity were used in each study.
It is interesting to note that the amount of time a patient was on NIV therapy had a significant association
with the need to be intubated. When looking at the amount of time a patient was on NIV, patients who
received HFNC were on therapy significantly longer than those that received CPAP or BiPAP.
When looking at the use of HFNC therapy in post extubation acute respiratory failure, findings in
this study suggest that HFNC therapy had no significant difference in effecting the rate of re-intubation.
This finding suggests that HFNC therapy is non-inferior to CPAP or BiPAP in reducing the need for reintubation in patients that experience respiratory failure after being liberated from mechanical ventilation.
These findings are consistent with those found by Hernadez et al. (2016) and Stephan et al. (2015). The
number of subjects requiring re-intubation was also similar across studies, Hernadez et al, 2015 (HFNC
22.8%, CPAP/BiPAP 19.1%) and Stephan et al., 2016 (HFNC 21%, CPAP/BiPAP 21.9%). Analysis of
Group 2 suggests that there is no significant difference between the time NIV therapy was started and the
need for intubation. As with Stephan et al. (2016), this study found that there was no significant
reduction in mortality between HFNC therapy and CPAP/BiPAP when used to treat post extubation acute
respiratory failure.
Within both Group 1 and Group 2, the effects of various FiO2 and LPM settings were examined
to determine associations with improved clinical outcomes (need for intubation or re-intubation, the
hospital length of stay and mortality). In comparing the interquartile ranges for FiO2 and LPM, this study
suggests that there is no significant difference between HFNC therapy initial settings and clinical
outcomes. This finding suggests that variations in the amount of oxygen subjects received and the rate at
which it was delivered have no impact on whether a patient died, required intubation or re-intubation and
the hospital length of stay. The inability of this study to detect a significant difference between FiO2 and
LPM setting and the need for intubation or re-intubation could be due to the study being underpowered.
In this study, current practices for HFNC therapy were assessed. It was found that there was a
large variance in practices in the initial settings that are used. In Group 1, FiO2 setting ranged from 40%
to 100% with a median of 70%. The flow rate was also found to have a large variance in the settings that
were administered. Patients in Group1 received oxygen at a flow rate ranging from 9 LPM to 40 LPM,
with a median flow rate of 25 LPM. In Group 2, there were a variety of HFNC settings for FiO2 and
LPM used for initial therapy. Flow rates in this group ranged from 10 to 40 LMP with a median flow rate
of 25 LPM. This study suggests that in current practice no equipoise of practice exists for initial settings
of HFNC therapy.
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Limitations and Strengths
A limitation of this study was the design. This study was designed to be a non-experimental,
retrospective, medical chart review. This is a known limitation because the data collected in the chart
audit relied on the documentation of others. Missing data in the charts led to the exclusion of 99 patients
from the study. This reduced the sample size, which may have reduced the ability of the study to discover
any significant association between variables. There were fewer patients in Group 2 than in Group 1.
Group 2 had an unequal distribution of subjects between NIV therapies. These factors could have skewed
results and prevented significance from being detected.
One strength of this study was the inclusion criteria for subjects. Examination of a broad class of
patient syndromes under the DRG parameters of acute respiratory failure may allow these results to be
more generalizable. Another strength of this study was that the inclusion and exclusion criteria were
determined prior to data extraction from the electronic medical record. In addition, the delineated
structured randomized selection of patients was done to mitigate the risk of selection bias.
Call for Future Research
Further research into the effects of HFNC therapy is needed. Large, robust, multicenter,
prospectus, randomized controlled trials need to be conducted to establish the relationship between HFNC
therapy vs. CPAP or BiPAP and intubation and in re-intubation rates. As noted in the discussion, further
studies need to illuminate the effects that delays in the initiation of post mechanical ventilator NIV have
on intubation rates. Continued research on this topic could increase knowledge of the best practices for
de-escalation of therapy. Further research needs to be conducted to better establish how various HFNC
FiO2 and LPM settings impact patient care and clinical outcomes. Increased research in this area can lead
to a better understanding of HFNC therapy and help guide best practices for initiation and titration of
therapy.
Conclusion
The aim of this study was to assess current practices of HFNC therapy to determine if it had an
impact on intubation rates and clinical outcomes, as well as describe current practices to help guide
clinicians in their use of HFNC therapy. HFNC therapy has been shown to be non-inferior to CPAP or
BiPAP in reducing the need for intubation/re-intubation, and clinical outcomes between groups were
similar. This combined with previous research demonstrating increased patient tolerance of HFNC
therapy should lead to the continued adoption and use of this therapy. This study was unable to establish
which setting of FiO2 and LPM would be a best practice for this therapy. As a result, clinicians should
use their clinical expertise and patient response to guide which setting to use in the initiation of this
therapy until future research can establish which settings are best practice.
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Table 1
Data points collected
Data recorded
Age
Sex
Primary diagnosis
Vital signs (HR, BP, Sp02, respiratory rate
Arterial Blood gases (ABGs)
Noninvasive ventilation Type and Settings (HFNC or
BIPAP/CPAP, and FiO2 and O2 L/min)
Ventilator settings (Mode, tidal volume, rate, FiO2,
PEEP)
Time on Noninvasive ventilation
Oxygen settings
PaO2/FiO2 ratio
Time of intubation
Time of extubation
Length of stay
Disposition
DRG

Time data recorded
At time of admission
At time of admission
At time of admission
Every 4 hours starting at 0700, closest value
Closest value1 hour, 6 hours and 12 hours post oxygen
supportive therapy initiation
Hourly setting and Type
First documented settings of the day
Documented start of noninvasive ventilation therapy to
time of intubation
Every 4 hours starting at 0700, closest value
Closest value 1hour, 6 hours, 12 hours post noninvasive
ventilation therapy
Chest x-ray confirming endotracheal tube placement
Documented time of extubation in chart
Time of admission to time of d/c or death
Time of discharge home or time of death
At time of discharge
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Table 2
Characteristics of Group 1
NIV therapy

Age, mean + SD

Sex, % (n)

LOS, median

DRG, median

Mortality, % (n)

HFNC

57.80 + 16.66

M: 48.9% (43)

14.82 days

3.16

Alive: 72.7% (64)

n=88

CPAP or BiPAP

F: 51.1% (45)

58.92 + 14.11

n=125
p value

M: 58.4% (73)

Expired: 27.3% (24)

10.65 days

1.88

F: 41.6% (52)
p=0.188

p=0.216

Alive: 77.6% (97)
Expired: 22.4% (28)

p=0.048

p=0.046

p=0.415
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Table 3
Group 1: HFNC vs. CPAP or BiPAP and Intubation
HFNC therapy

CPAP or BiPAP

p value

Time on NIV, median

6.50 hours

4.0 hours

p= <0.001

Time on vent post NIV, median

94.0 hours

90.0 hours

p= 0.801

Need for intubation, % (no.)

Yes: 24.4% (30)

Yes: 35.2% (31)

p= 0.119

No: 75.6% (93)

No: 64.8 % (57)
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Table 4
Group 1: HFNC FiO2 Setting and Clinical Outcomes
Quartile (range)

Q1 (40-55%)

Mortality, % (no.)

Alive: 76.2% (16)

LOS, median

12.17 days

Expired: 23.8% (5)
Q2 (56-70%)

Alive: 80% (16)

Alive: 85.7% (12)

12.50 days

Alive: 56.7% (17)

32.94 days

p= 0.099

%(no.)

median

Yes: 38.1% (8)

51 hours

3.80

94 hours

3.42

267 hours

5.31

96 hours

1.81

p= 0.082

p= 0.003

Yes: 35% (7)

Yes: 42.9% (6)
No: 57.1% (8)

11.70 days

Expired: 43.3% (13)
p value

DRG, Median

No: 65% (13)

Expired: 14.3% (2)
Q4 (100%)

Time on vent,

No: 61.9% (13)

Expired: 20% (4)
Q3 (71-99%)

Vent need,

Yes: 36.7% (11)
No: 63.3% (19)

p= 0.062

p= 0.992
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Table 5
Group 1: HFNC LPM Setting and Clinical Outcomes
Quartile (range)

Q1 (9-20 LPM)

Mortality, % (no.)

Alive: 75% (9)

LOS, median

2.77 days

Expired: 25% (3)
Q2 (21-25 LPM)

Alive: 65.4% (17)

Alive: 68.4% (13)

12.78 days

Alive: 78.6% (22)

17.77 days

p= 0.502

%(no.)

median

Yes: 41.7% (5)

51 hours

2.05

42 hours

5.00

191 hours

6.85

87 hours

5.08

p= 0.046

p= 0.692

Yes: 34.6% (9)

Yes: 47.4% (9)
No: 52.6% (10)

14.65 days

Expired: 21.4% (6)
p value

DRG, Median

No: 65.4% (17)

Expired: 31.6% (6)
Q4 (30-40 LPM)

Time on vent,

No: 58.3% (7)

Expired: 34.6% (9)
Q3 (26-30 LPM)

Vent need,

Yes: 32.1% (9)
No: 67.9% (19)

p= 0.476

p= 0.716
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Table 6
Characteristics of Group 2
NIV Therapy
HFNC

Age, mean + SD

Sex, % (no.)

LOS, median

DRG, median

Mortality, % (no.)

51.50 + 16.94

M: 62.9% (39)

16.08

5.17

Alive: 85.5% (53)

n=62
CPAP or

F: 37.1% (23)
58.62 + 15.25

BiPAP
n=26
p value

M: 50% (13)

Expired: 14.5% (9)
18.16

5.37

F: 50% (13)
p= 0.041

p= 0.376

Alive: 88.5% (23)
Expired: 11.5% (3)

p= 0.387

p= 0.905

p= 0.975
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Table 7
Group 2: HFNC vs. CPAP or BiPAP and Re-intubation

Time on NIV, median
Need for re-intubation, %, (no.)

Delay in NIV post vent, median

HFNC therapy

CPAP or BiPAP

p value

34 hours

8.50 hours

p= <0.001

Yes: 26.9% (7)

Yes: 23.8% (15)

p= 0.969

No: 73.1% (19)

No: 71.6% (48)

3 hours

1 hour

p= 0.168
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Table 8
Group 2: HFNC FiO2 Setting and Clinical Outcomes
Quartile (range)

Mortality, % (no.)

LOS, median

Vent need, %(no.)

DRG, Median

Q1 (21-40%)

Alive: 98.3% (15)

17.68 days

Yes: 31.3% (5)

5.54

Expired: 6.3% (1)
Q2 (41-50%)

Alive: 88.2% (15)

No: 68.8% (11)
15.89 days

Expired: 11.8% (2)
Q3 (51-70%)

Alive: 81.8 % (9)

Alive: 77.8% (14)

17.38 days

p= 0.167

Yes: 18.2 % (2)

5.34

No: 81.8 % (9)
14.50 days

Expired: 22.2 (4)
p value

3.10

No: 88.2% (15)

Expired: 18.2% (2)
Q4 (71-100%)

Yes: 11.8% (2)

Yes: 33.3% (6)

5.04

No: 66.7% (12)
p= 0.409

p= 0.749

p= 0.486

THE EFFECTS OF HFNC THERAPY AND INTUBATION

18

Table 9
Group 2: HFNC LPM Setting and Clinical Outcomes
Quartile (range)

Mortality, % (no.)

LOS, median

Vent need, %(no.)

DRG, Median

Q1 (10-20 LPM)

Alive: 87.2 % (7)

25.28 days

Yes: 37.5% (3)

5.56

Expired: 12.5 % (1)
Q2 (21-25 LPM)

Alive: 82.4 % (14)

No: 62.5% (5)
13.91 days

Expired: 17.6% (3)
Q3 (26-30 LPM)

Alive: 82.8% (24)

Alive: 100% (8)

18.63 days

p= 0.554

Yes: 24.1% (7)

5.21

No: 75.9 % (22)
16.15 days

Expired: 0% (0)
p value

5.03

No: 88.2% (15)

Expired: 17.2% (5)
Q4 (31-40 LPM)

Yes: 11.8 % (2)

p= 0.146

Yes: 24.2% (3)
No: 75.8% (5)

2.99

p= 0.596

p= 0.423
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Table 10
FiO2 Settings and Time on NIV
Quartiles

Group 1 median time on NIV

Group 2 median time on NIV

Q1

12.00 hours

41.50 hours

Q2

14.00 hours

41.00 hours

Q3

25.00 hours

24.00 hours

Q4

37.50 hours

34.50 hours

p= 0.103

p= 0.624

p value
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Table 11
LPM Settings and Time on NIV
Quartiles

Group 1 median time on NIV

Group 2 median time on NIV

Q1

5.50 hours

10.0 hours

Q2

30.50 hours

41.00 hours

Q3

25.00 hours

40.00 hours

Q4

30.50 hours

35.50 hours

p= 0.033

p= 0.039

p value

20
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Sample	
  

	
  46,218	
  Adult	
  admissions	
  at	
  UK	
  Chandler	
  Hospital	
  July,	
  1	
  2011-‐July1,	
  2014	
  

1,885	
  with	
  primary	
  or	
  secondary	
  diagnosis	
  of	
  Acute	
  Respiratory	
  Failure	
  and	
  on	
  HFNC	
  or	
  CPAP/BiPAP	
  

329	
  soley	
  receiving	
  HFNC	
  

329	
  soley	
  receiving	
  CPAP	
  or	
  BiPAP	
  

1,227	
  receiving	
  both	
  therapies	
  

658	
  soley	
  receiving	
  HFNC	
  or	
  CPAP	
  Or	
  BiPAP	
  

200	
  HFNC	
  randomly	
  selected	
  

200	
  CPAP	
  or	
  BiPAP	
  randomly	
  selected.	
  

Group	
  1	
  

308	
  pa*ents	
  receiving	
  NIV	
  pre	
  intuba*on	
  

Group	
  2	
  

92	
  pa*ents	
  receiving	
  NIV	
  post	
  extuba*on	
  

Figure 1. Sample Selection
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